ClinicalTrials.gg

Program

elamipretide

Also written as “MTP-131”, “Elamipretide” and “Bendavia”.

Its studies are mostly in Heart Failure · Macular Degeneration · Mitochondrial Myopathies · Mitochondrial Diseases · Muscular Diseases, led by Mighty Therapeutics.

Furthest: phase 4, since Mar 12, 202627 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mighty Therapeutics273 open or runningphase 4since Mar 12, 2026Apr 30, 2010May 2027phase 1 · NCT07927972

Also a collaborator on its studies: icon-clinical-research.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Apr 30, 2010.

  1. Apr 30, 2015Phase 1 study in Renal InsufficiencyNCT02436447 · 23 enrolled · United States
  2. Feb 15, 2016Phase 2 study in Optic Atrophy, Hereditary, LeberNCT02693119 · 12 enrolled · United States
  3. May 27, 2016Phase 2 study in Heart FailureNCT02788747 · 71 enrolled · Italy, Netherlands, United Kingdom
  4. Jun 8, 20162 phase 2 studiesNCT02814097, NCT02805790
  5. Jul 25, 2016Phase 1 study in Macular DegenerationNCT02848313 · 40 enrolled · United States
  6. Sep 14, 2016Phase 2 study in Heart FailureNCT02914665 · 308 enrolled · Belgium, Bulgaria, France and more
  7. Nov 18, 2016Phase 2 study in Primary Mitochondrial DiseaseNCT02976038 · 28 enrolled · United States
  8. Mar 21, 2017Phase 3 study in Barth SyndromeNCT03098797 · 12 enrolled · United States
  9. Oct 12, 2017Phase 3 study in Muscular DiseasesNCT03323749 · 218 enrolled · United States, Canada, Denmark and more
  10. Mar 25, 2019Phase 2 study in Macular DegenerationNCT03891875 · 176 enrolled · United States
  11. Dec 8, 2021Phase 3 study in Mitochondrial MyopathiesNCT05162768 · 102 enrolled · United States, Australia, Germany and more
  12. Apr 16, 2024Phase 3 study in Macular DegenerationNCT06373731 · 313 enrolled · United States, Czechia, Germany and more
  13. Mar 12, 2026Phase 4 study in Barth SyndromeNCT07531251 · 48 planned · United States, Australia, Canada and more
  14. Oct 23, 2026Phase 1 study in Barth SyndromeNCT07927972 · 6 planned

Ahead

  1. May 2027Primary completion: phase 1 study in Barth SyndromeNCT07927972
  2. Aug 2027Primary completion: phase 3 study in Macular DegenerationNCT06373731
  3. Sep 30, 2029Primary completion: phase 4 study in Barth SyndromeNCT07531251

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07927972Barth Syndrome1Not yet recruitingMay 20276
NCT07531251Barth Syndrome · United States, Australia, Canada and more4RecruitingSep 30, 202948
NCT06373731Macular Degeneration · United States, Czechia, Germany and more3Active, not recruitingAug 2027313
NCT05162768Mitochondrial Myopathies · United States, Australia, Germany and more3CompletedSep 30, 2024102
NCT03891875Macular Degeneration · United States2CompletedFeb 22, 2022176
NCT03323749Muscular Diseases · United States, Canada, Denmark and more3TerminatedFeb 10, 2020218
NCT03098797Barth Syndrome · United States3CompletedOct 5, 201812
NCT02976038Primary Mitochondrial Disease · United States2TerminatedMar 9, 202028
NCT02914665Heart Failure · Belgium, Bulgaria, France and more2CompletedNov 27, 2017308
NCT02848313Macular Degeneration · United States1CompletedMar 16, 201840
NCT02805790Mitochondrial Myopathies · United States2CompletedMar 10, 201730
NCT02814097Heart Failure · Germany, Serbia2CompletedMay 4, 201746
NCT02788747Heart Failure · Italy, Netherlands, United Kingdom2CompletedSep 201771
NCT02693119Optic Atrophy, Hereditary, Leber · United States2CompletedSep 201912
NCT02436447Renal Insufficiency · United States1CompletedJul 201523
NCT02388529Heart Failure · Bulgaria1WithdrawnSep 20150
NCT02388464Heart Failure · Bulgaria1CompletedApr 201536
NCT02367014Mitochondrial Myopathies · United States2CompletedApr 201636
NCT02314299Macular Degeneration · United States2CompletedMay 201520
NCT02245620Skeletal Muscle Mitochondrial Dysfunction in the Elderly · United States2CompletedJul 6, 201641
NCT01786915Healthy Volunteers · United States1CompletedMar 201330
NCT01755858Renal Artery Obstruction · United States2TerminatedDec 201516
NCT01754818Healthy · United States1CompletedJan 201330
NCT01572909Reperfusion Injury · United States, Germany, Hungary and more2CompletedNov 2014300
NCT01518985Healthy Volunteers · United States1CompletedMar 20126
NCT01513200Healthy Volunteers · United States1CompletedFeb 201212
NCT01115920Healthy · United States1CompletedSep 201040

How it is read

Names in the registry

  • “MTP-131”, 11 entries
  • “Elamipretide”, 8 entries
  • “elamipretide”, 4 entries
  • “Bendavia”, 3 entries
  • “Bendavia 10mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
elamipretide (Mighty Therapeutics): development program | ClinicalTrials.gg